Information Provided By: 
Fly News Breaks for May 17, 2018
EPZM
May 17, 2018 | 11:30 EDT
After abstracts were released ahead of the ASCO meeting for new and updated Phase II tazemetostat data in mesothelioma and "more importantly" follicular lymphoma data to be presented at the EHA meeting, Jefferies analyst Michael Yee said the new lymphoma abstract data "looks solid." The high responses rates support Yee's view that tazemetostat looks like "an approval and attractive cancer drug," he tells investors. Yee keeps a Buy rating on Epizyme with a $27 price target.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
